Epitope engineering and molecular metrics of immunogenicity: A computational approach to VLP-based vaccine design

Vaccine

Volumn 31, Issue 42, 2013, Pages 4841-4847

  Joshi, Harshad ^a   Lewis, Kristen ^a,b   Singharoy, Abhishek ^a   Ortoleva, Peter J ^a  

^a INDIANA UNIVERSITY   (United States)

^b JACKSON STATE UNIVERSITY   (United States)

Author keywords

Antibody virus binding; Computer aided vaccine design; Infectious diseases; Molecular metric of immunogenicity

Indexed keywords

EPITOPE; HEPATITIS B VACCINE; VIRUS LIKE PARTICLE VACCINE;

ANTIBODY AFFINITY; ARTICLE; BINDING AFFINITY; BIOENGINEERING; COMPUTER AIDED DESIGN; COMPUTER SIMULATION; DRUG DESIGN; HEPATITIS B VIRUS; IMMUNOGENICITY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; VIRUS LIKE AGENT; WART VIRUS;

ANTIBODY-VIRUS BINDING; COMPUTER-AIDED VACCINE DESIGN; INFECTIOUS DISEASES; MOLECULAR METRIC OF IMMUNOGENICITY;

ANTIBODIES, VIRAL; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; EPITOPES; HEPATITIS B VIRUS; HUMANS; PAPILLOMAVIRIDAE; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 84884210746     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.075     Document Type: Article

References (50)

1. Plummer E.M., Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2011, 3(2):174-196.
2. López-Macías C. Virus-like particle (VLP)-based vaccines for pandemic influenza: Performance of a VLP vaccine during the 2009 influenza pandemic. Human Vaccines and Immunotherapeutics 2012, 8(3):411-414.
3. Buonaguro L., Tornesello M., Buonaguro F. Virus-like particles (VLPs) as anti-viral vaccines: an effective approach for a HIV-1 vaccine strategy. ASHI Quarterly 2005, (2nd Quarter):10-13.
4. Mach H., Volkin D.B., Troutman R.D., Wang B., Luo Z., Jansen K.U., et al. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). Journal of Pharmaceutical Sciences 2006, 95(10):2195-2206.
5. Jennings G.T., Bachmann M.F., Immunodrugs Therapeutic VLP-based vaccines for chronic diseases. Annual Review of Pharmacology and Toxicology 2009, 49:303-326.
6. Brown D.R., Garland S.M., Ferris D.G., Joura E., Steben M., James M., et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Human Vaccines 2011, 7(2):230-238.
7. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Human Vaccines 2009, 5(10):705-719.
8. Akahata W., Yang Z.Y., Andersen H., Sun S., Holdaway H.A., Kong W.P., et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nature Medicine 2010, 16:334-338.
9. Li T.C., Suzaki Y., Ami Y., Dhole T.N., Miyamura T., Takeda N. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine 2004, 22(3-4):370-377.
10. Vicente T., Roldão A., Peixoto C., Carrondo M.J., Alves P.M. Large-scale production and purification of VLP-based vaccines. Journal of Invertebrate Pathology 2011, 107(Suppl. (0)):S42-S48.
11. Li T.C., Takeda N., Miyamura T., Matsuura Y., Wang J.C., Engvall H., et al. Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. Journal of Virology 2005, 79(20):12999-13006.
12. Grgacic E.V.L., Anderson D.A. Virus-like particles: passport to immune recognition. Methods 2006, 40(1):60-65.
13. Joshi H., Cheluvaraja S., Somogyi E., Brown D.R., Ortoleva P. A molecular dynamics study of loop fluctuation in human papillomavirus type 16 virus-like particles: a possible indicator of immunogenicity. Vaccine 2011, 29(51):9423-9430.
14. Murata Y., Lightfoote P.M., Rose R.C., Walsh E.E. Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virology Journal 2009, 6(1):81.
15. Bishop B., Dasgupta J., Chen X. Structure-based engineering of papillomavirus major capsid L1: controlling particle assembly. Virology Journal 2007, 4:3.
16. Rohs R., Bloch I., Sklenar H., Shakked Z. Molecular flexibility in ab initio drug docking to DNA: binding-site and binding-mode transitions in all-atom Monte Carlo simulations. Nucleic Acids Research 2005, 33(22):7048-7057.
17. Reddy M.R., Erion M.D. Free Energy Calculations in Rational Drug Design 2001, Springer Verlag, New York.
18. Leaver-Fay A., Tyka M., Lewis S.M., Lange O.F., Thompson J., Jacak R., et al. Rosetta3: an object-oriented software suite for the simulation and design of macromolecules. Methods in enzymology 2011, 487:545-574.
19. Azoitei M.L., Correia B.E., Ban Y-E.A., Carrico C., Kalyuzhniy O., Chen L., et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science. 2011, 334(6054):373-376.
20. Nowak M.A. Immune responses against multiple epitopes: a theory for immunodominance and antigenic variation. Seminars in Virology 1996, 7:83-92.
21. Roden R.B., Yutzy W.H., Fallon R., Inglis S., Lowy D.R., Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000, 270(2):254-257.
22. Kringelum J.V., Nielsen M., Padkjær S.B., Lund O. Structural analysis of B-cell epitopes in antibody:protein complexes. Molecular Immunology 2013, 53(1-2):24-34.
23. Ramaraj T., Angel T., Dratz E.A., Jesaitis A.J., Mumey B. Antigen-antibody interface properties: composition, residue interactions, and features of 53 non-redundant structures. Biochimica et Biophysica Acta 2012, 1824(3):520-532.
24. Joshi H., Singharoy A., Sereda Y.V., Cheluvaraja S.C., Ortoleva P.J. Multiscale simulation of microbe structure and dynamics. Progress in Biophysics and Molecular Biology 2011, 107(1):200-217.
25. Singharoy A., Sereda Y.V., Ortoleva P.J. Hierarchical order parameters for macromolecular assembly simulations I: construction and dynamical properties of order parameters. Journal of Chemical Theory and Computation 2012, 8(4):1379-1392.
26. Sadeyen J.R., Tourne S., Shkreli M., Sizaret P.Y., Coursaget P. Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology 2003, 309(1):32-40.
27. Chi S.W., Maeng C.Y., Kim S.J., Oh M.S., Ryu C.J., Kim S.J., et al. Broadly neutralizing anti-hepatitis B virus antibody reveals a complementarity determining region H3 lid-opening mechanism. Proceedings of the National Academy of Sciences 2007, 104(22):9230-9235.
28. Bishop B., Dasgupta J., Klein M., Garcea R.L., Christensen N.D., Zhao R., et al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. Journal of Biological Chemistry 2007, 282(43):31803-31811.
29. Liang T.J., Hepatitis B. The virus and disease. Hepatology 2009, 49(S5):S13-S21.
30. Humphrey W., Dalke A., Schulten K. VMD, visual molecular dynamics. Journal of Molecular Graphics 1996, 14(1):33-38.
31. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., et al. Scalable molecular dynamics with NAMD. Journal of Computational Chemistry 2005, 26(16):1781-1802.
32. MacKerell A.D., Bashford D., Bellott M., Evanseck D.R.L.J., Field M.J., Fischer S., et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. Journal of Physical Chemistry B 1998, 102(18):3586-3616.
33. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics 1983, 79:926.
34. Feller S.E., Zhang Y., Pastor R.W., Brooks B.R. Constant pressure molecular dynamics simulation: the Langevin piston method. Journal of Chemical Physics 1995, 103:4613-4621.
35. Schlick T., Skeel R.D., Brunger A.T., Kalé L.V., Board J.A., Hermans J., et al. Algorithmic challenges in computational molecular biophysics. Journal of Computational Physics 1999, 151(1):9-48.
36. Singharoy A., Joshi H., Ortoleva P.J. Multiscale macromolecular simulation: role of evolving ensembles. Journal of Chemical Information and Modeling 2012, 52(10):2638-2649.
37. Singharoy A., Joshi H., Miao Y., Ortoleva P.J. Space warping order parameters symmetry: application to multiscale simulation of macromolecular assemblies. Journal of Physical Chemistry B 2012, 116(29):8423-8434.
38. Cheluvaraja S., Ortoleva P. Thermal nanostructure: an order parameter/multiscale ensemble approach. Journal of Chemical Physics 2010, 132(7):075102.
39. Thönes N., Herreiner A., Schädlich L., Piuko K., Müller M. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. Journal of Virology 2008, 82(11):5472-5485.
40. Singharoy A., Cheluvaraja S., Ortoleva P.J. Order Parameters for Macromolecules: Application to Multiscale Simulation. Journal of Chemical Physics 2011, 134:044104.
41. Sereda Y., Singharoy A., Jarrold M.F., Ortoleva P.J. An information theory approach to multiple free-energy basin discovery. Journal of Physical Chemistry B 2012, 116:8534.
42. Sereda Y.V., Ortoleva P.J. Variational principles and multiscaling for time-dependent many-particle classical systems. Physica A 2012, 392(4):628-638.
43. Quick R., Singharoy A., Ortoleva P. Quasiperiodic oscillation and possible Second Law violation in a nanosystem. Chemical Physics Letter 2013, 571:61-65.
44. Pankavich S.D., Ortoleva P.J. Nanosystem self-assembly pathways discovered via all-atom multiscale analysis. Journal of Physical Chemistry B 2012, 116(29):8355-8362.
45. Ortoleva P., Singharoy A., Pankavich S. Hierarchical multiscale modeling of macromolecules and their assemblies. Soft Matter 2013, 9:4319-4335.
46. Singharoy A., Cheluvaraja S., Ortoleva P.J. Order parameters for macromolecules: application to multiscale simulation. Journal of Chemical Physics 2011, 134:044104.
47. Barrozo A., Borstnar R., Marloie G., Kamerlin S.C.L. Computational protein engineering: bridging the gap between rational design and laboratory evolution. International Journal of Molecular Sciences 2012, 13(10):12428-12460.
48. Sablon E., Shapiro F. Advances in molecular diagnosis of HBV infection and drug resistance. International Journal of Medical Sciences 2005, 2(1):8-16.
49. Zoulim F., Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver International 2013, 33:116-124.
50. Goldberg D.E., Siliciano R.F., Jacobs W.R. Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 2012, 148(6):1271-1283.